Soligenix Inc.
$ 1.38
10.40%
20 Apr - close price
- Market Cap 12,882,600 USD
- Current Price $ 1.38
- High / Low $ 1.42 / 1.26
- Stock P/E N/A
- Book Value 0.52
- EPS -2.14
- Next Earning Report 2026-05-08
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.81 %
- ROE -2.36 %
- 52 Week High 6.23
- 52 Week Low 1.00
About
Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. The company is headquartered in Princeton, New Jersey.
Analyst Target Price
$15.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-31 | 2025-12-31 | 2025-11-07 | 2025-08-14 | 2025-05-08 | 2025-03-13 | 2024-11-11 | 2024-08-09 | 2024-05-10 | 2024-03-15 | 2023-11-13 | 2023-08-21 |
| Reported EPS | -0.2871 | None | -0.58 | -0.82 | -1.06 | -1.14 | -0.78 | -1.31 | -0.18 | -0.23 | -0.16 | -0.22 |
| Estimated EPS | None | -0.27 | -0.12 | -0.11 | -0.67 | -1.56 | -1.09 | -1.77 | -0.19 | -0.19 | -0.29 | -0.49 |
| Surprise | 0 | 0 | -0.46 | -0.71 | -0.39 | 0.42 | 0.31 | 0.46 | 0.01 | -0.04 | 0.13 | 0.27 |
| Surprise Percentage | None% | None% | -383.3333% | -645.4545% | -58.209% | 26.9231% | 28.4404% | 25.9887% | 5.2632% | -21.0526% | 44.8276% | 55.102% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-08 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNGX
2026-04-20 21:40:17
Soligenix (NASDAQ: SNGX) has received orphan drug designation from the European Commission for its investigational therapy SGX945, intended for the treatment of Behet's disease. This designation validates the therapy's potential and the company's development strategy, particularly for rare diseases. SGX945 is based on dusquetide, a synthetic peptide that belongs to a class of innate defense regulators.
2026-04-20 18:09:20
The European Commission has granted orphan drug designation to Soligenix's investigational therapy SGX945 for the treatment of Behçet’s disease, validating the therapy's potential. This designation encourages the development of treatments for rare diseases within the EU. SGX945 is based on dusquetide, a synthetic peptide that belongs to a class of compounds known as innate defense regulators.
2026-04-20 17:40:17
Soligenix announced that the European Commission granted orphan drug designation to its investigational therapy SGX945 for the treatment of Behçet’s disease. This designation reinforces the potential of SGX945, which is based on dusquetide (an innate defense regulator), and validates the company's development strategy, particularly in the rare disease space. Orphan drug designation in the EU encourages the development of treatments for rare diseases, highlighting the significance of this recognition for Soligenix.
2026-04-18 18:09:12
Soligenix (NASDAQ: SNGX) has provided a positive clinical update on its research into cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma. The company reported consistent overall blinded aggregate response rates from its phase 3 FLASH2 study and positive comparative results for its HyBryte™ therapy against an existing treatment, Valchlor®. These updates reinforce Soligenix's commitment to developing innovative treatments for conditions with limited options.
2026-04-18 17:10:10
Soligenix (NASDAQ: SNGX) has provided a positive clinical update for its HyBryte therapy, which is focused on treating cutaneous T-cell lymphoma (CTCL). The company reported that the interim blinded aggregate response rate from its Phase 3 FLASH2 study remains consistent with previous findings, and a comparative study showed positive results for HyBryte against an existing treatment, Valchlor. This progress highlights Soligenix's commitment to developing innovative treatments for serious conditions like CTCL.
2026-04-18 11:40:00
Soligenix (SNGX) is making progress in its research for cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma. The company reported positive interim results from its phase 3 FLASH2 study and favorable comparative clinical results for its HyBryte therapy against an existing treatment option, Valchlor. This advancement reinforces Soligenix's dedication to developing innovative treatments for serious medical conditions.
